High-grade carcinoma in situ of the breast is an early stage cancer of the breast that can be cured basically by surgery and has a low chance of recurrence after surgery.
Surgical options include total mastectomy, breast-conserving surgery with mass removal, and whole-breast radiotherapy is recommended after breast-conserving surgery. The first step in the process is to remove the lump from the body, and the second step is to remove the lump from the body.
Current clinical studies have not demonstrated that the absence of chemotherapy in such patients increases the risk of subsequent recurrence and metastasis. If postoperative pathology immunohistochemistry suggests HER-2 positivity, this patient has HER-2 amplified breast cancer and may be considered for biologic targeted therapy. If the test is positive for both estrogen receptor (ER) and progesterone receptor (PR), it suggests that postoperative adjuvant endocrine therapy will be effective, and if the test is negative for both estrogen receptor (ER) and progesterone receptor (PR), endocrine therapy is basically ineffective. Endocrine therapy is one of the most convenient and safest treatments for breast cancer.